Kiran Mazumdar-Shaw names niece as successor, but she is ‘not hanging up boots yet’; who is Claire Mazumdar?
as Kiran Mazumdar-ShawThe founder and chairman of Biocon names his niece Claire Mazumdar as his successor and explains that the transition will come at an appropriate time. He added that he doesn’t plan to retire immediately.
Today she posted on X: “Claire will step into my role at the right time so I’m not planning on hanging up my boots just yet!!”
Kiran told Reuters He said he planned a gradual leadership transition over the next five years, with his niece Claire expected to take over the presidency in phases.
business magazine fortune india He first reported his succession plan in an interview with Kiran Mazumdar-Shaw.
In a recent interview with the magazine, Biocon’s boss revealed that he is currently focused on preparing the company for its next phase of growth, namely the integration of advanced biotechnology and artificial intelligence into its operations.
Who is Claire Mazumdar?
Claire, 37, is the founder and chief executive of Bicara Therapeutics, a Nasdaq-listed firm incubated by Biocon. He has held the position since 2018 and led the company’s IPO in 2024. Bicara focuses on developing cancer treatments, including bispecific antibodies, which are currently undergoing clinical trials.
He holds a degree in biological engineering from the Massachusetts Institute of Technology (MIT) and also earned both an MBA and a PhD from Stanford University.
Shreehas Tambe joins integrated Biocon as its first CEO
Shreehas Tambe joined Biocon as CEO and Managing Director effective April 1.
As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilar and generic medicines, strengthening the company’s ability to operate at scale and compete effectively in global markets, the company said in a statement.
Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said.
This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly owned subsidiary of Biocon Ltd, creating a simplified, unified corporate structure.
The strengthened organization is well positioned to provide leadership in diabetes, obesity, oncology and immunology through a differentiated portfolio of biosimilars, insulins, complex generics and peptides, including GLP-1 therapies, the company said.
